Zacks Investment ResearchFri, 08 May 2026 18:30:28 GMTTBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline HurdleTBPH-0.06%
Zacks Investment ResearchThu, 07 May 2026 14:50:20 GMTHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockTBPH-0.06%
Zacks Investment ResearchThu, 16 Apr 2026 18:15:35 GMTTheravance Stock Declines Around 17% in Three Months: Here's WhyTBPH-0.06%
Zacks Investment ResearchWed, 15 Apr 2026 14:50:24 GMTHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockTBPH-0.06%
Zacks Investment ResearchFri, 20 Mar 2026 19:46:05 GMTTheravance's Q4 Earnings and Revenues Miss EstimatesTBPH-0.06%
Zacks Investment ResearchFri, 20 Mar 2026 17:01:07 GMTAll You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong BuyTBPH-0.06%
Zacks Investment ResearchFri, 20 Mar 2026 14:45:23 GMTHere's Why Theravance Biopharma (TBPH) is a Strong Growth StockTBPH-0.06%
Zacks Investment ResearchThu, 19 Mar 2026 14:41:53 GMTTheravance Biopharma (TBPH) Q4 Earnings and Revenues Lag EstimatesTBPH-0.06%
Zacks Investment ResearchMon, 09 Mar 2026 14:35:43 GMTDown 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)TBPH-0.06%
Zacks Investment ResearchFri, 06 Mar 2026 15:35:22 GMTDown 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)TBPH-0.06%
Zacks Investment ResearchWed, 04 Mar 2026 16:35:48 GMTTBPH Stock Plunges 26% on Failure of Late-Stage MSA StudyTBPH-0.06%
BenzingaTue, 03 Mar 2026 18:19:37 GMTTheravance Biopharma Plummets As Phase 3 Study Falls ShortTBPH-0.06%
Investors Business DailyTue, 03 Mar 2026 17:14:04 GMTThe Excruciating Failure That Could Cause Theravance, Down 27%, To Sell ItselfTBPH-0.06%
